Angiogenesis in the pathobiology and treatment of vascular and malignant diseases

Annals of Thoracic Surgery

Volumn 64, Issue 4, 1997, Pages 1204-1211

  Winlaw, David S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; N(G) METHYLARGININE; NITRIC OXIDE; VASCULOTROPIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLATERAL CIRCULATION; GENE THERAPY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0030663627     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)00716-9     Document Type: Article

References (79)

1. Levy AP, Levy NS, Loscalzo J, et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res. 76:1995;758-766.
2. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. J Biol Chem. 266:1991;11947-11954.
3. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 56:1996;2013-2016.
4. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. Blood. 268:1993;21513-21518.
5. Mukhopadhyay D, Tsiokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375:1995;577-581.
6. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem. 271:1996;2746-2753.
7. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 94:1996;1647-1654.
8. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 90:1994;649-652.
9. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation. 92:1995;11-14.
10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
11. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
12. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 93:1996;2576-2581.
13. Grimmond S, Lagercrantz J, Drinkwater C, et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6:1996;124-131.
14. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15:1996;290-298.
15. Stavri GT, Hong Y, Zachary IC, et al. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 358:1995;311-315.
16. Li J, Perella MA, Tsai J-C, et al. Induction of vascular endothelial growth factor gene expression by interleukin-1β in rat aortic smooth muscle cells. J Biol Chem. 270:1995;308-312.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:1995;27-31.
18. Carr S, Farb A, Pearce WH, Virmani R, Yao JST. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis. J Vasc Surg. 23:1996;755-766.
19. Casscells W, Hathorn B, David M, et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques possible implications for plaque rupture and thrombosis . Lancet. 347:1996;1447-1449.
20. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ. T Lymphocytes that infiltrate tumours and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci USA 1995;92:6547-1.
21. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
22. Fryer JA, Myers PC, Appleberg M. Carotid intraplaque hemorrhage the significance of neovascularity . J Vasc Surg. 6:1987;341-349.
23. Bo WJ, Mercuri M, Tucker R, Bond MG. The human carotid atherosclerotic plaque stimulates angiogenesis on the chick chorioallantoic membrane. Atherosclerosis. 94:1992;71-78.
24. O'Brien ER, Garvin MR, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 145:1994;883-894.
25. Zemplenyi T, Crawford DW, Cole MA. Adaptation to arterial wall hypoxia demonstrated in vivo with oxygen microcathodes. Atherosclerosis. 76:1989;173-179.
26. Kuzuya M, Stake S, Yamada K, et al. Induction of angiogenesis by smooth muscle cell-derived factor possible role in neovascularization in atherosclerotic plaque . J Cell Physiol. 164:1995;658-667.
27. Booth RFG, Martin JF, Honey AC, Hassall DG, Beesley JE, Moncada S. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis. 76:1989;257-268.
28. Brogi E, Winkles J, Libby P. Regional expression of acidic and basic fibroblast growth factor in human atheroma and non-atherosclerotic arteries [Abstract]. Circulation. 86:(Suppl 1):1990;85.
29. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 94:1996;1655-1664.
30. Nabel EG, Yang Z-Y, Plautz G, et al. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature. 362:1993;844-846.
31. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 89:1992;465-473.
32. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
33. Libby P, Ross R. Cytokines and growth regulatory molecules. Fuster V, Ross R, Topol E. Atherosclerosis and coronary artery disease. 1996;5985-5994 Lippincott-Raven, New York.
34. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide - physiology, pathophysiology, and pharmacology. Pharmacol Rev. 43:1991;109-142.
35. Meurice T, Bauters C, Auffray J-L, et al. Basic fibroblast growth factor restores endothelium-dependent responses after balloon injury of rabbit arteries. Circulation. 93:1996;18-22.
36. Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 91:1995;2793-2801.
37. Yamamoto K, Takahashi K, Dzau VJ, Pratt RE. Human VEGF gene transfer into vascular prostheses [Abstract]. Circulation. 94:(Suppl 1):1996;637.
38. Bauters C, Asahara T, Zheng LP, et al. Site specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg. 21:1995;314-325.
39. 165 in patient with ischaemic limb. Lancet. 348:1996;370-374.
40. Tsurumi Y, Kearney M, Chen D, et al. Gene transfer into acute ischaemic skeletal muscles with naked DNA encoding vascular endothelial growth factor augments collateral vessel development [Abstract]. Circulation. 94:(Suppl 1):1996;234.
41. Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia implications for coronary angiogenesis . Cardiovasc Res. 28:1994;1176-1179.
42. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol. 270:(Heart Circ Physiol 39):1996;H1803-H1811.
43. Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischaemia. Am J Physiol. 270:(Heart Circ Physiol 39):1996;H1791-H1802.
44. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res. 63:1996;77-82.
45. Yang R, Thomas GR, Bunting S, et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol. 27:1996;838-844.
46. Horrigan MCG, MacIsaac AI, Nicolini FA, et al. Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model. Circulation. 94:1996;1927-1933.
47. Mazué G, Bertolero F, Garofano L, Brughera M, Carminati P. Experience with the preclinical assessment of basic fibroblast growth factor (bFGF). Toxicol Lett 1992;64-65:329-38.
48. Mazué G, Newman AJ, Scampini G, et al. The histopathology of kidney changes in rats and monkeys following intravenous administration of massive doses of FCE 26184, human basic fibroblast growth factor. Toxicol Pathol. 21:1993;490-501.
49. Lazarous DF, Shou M, Scheinowitz M, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation. 94:1996;1074-1082.
50. Morbidelli L, Chang C-H, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol. 39:1996;H411-H415.
51. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 98:1996;1667-1675.
52. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. J Clin Invest. 95:1995;1798-1807.
53. Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res. 2:1996;1411-1416.
54. Holm C, Gineitis D, McConville GS, Kazlauskas A. Expression of PDGF, VEGF and their receptors in non-small cell lung tumor cell lines. Int J Oncol. 9:1996;1077-1086.
55. Takanami I, Tanaka F, Hashizume T, Kodaira S. Pulmonary adenocarcinoma angiogenesis a study of factors that may influence tumor angiogenesis and survival . Int J Oncol. 10:1997;101-106.
56. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulated VEGF/VPF expression implications for induction and inhibition of tumor angiogenesis . Cancer Res. 55:1995;4575-4580.
57. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:1995;6161-6165.
58. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
59. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 56:1996;3436-3440.
60. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. 56:1996;921-924.
61. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma . Cell. 79:1994;315-328.
62. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med. 2:1996;992-997.
63. Harpole DHJ, Richards WG, Herndon JE II, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I small cell lung cancer. Ann Thorac Surg. 61:1996;1470-1476.
64. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56:1996;172-181.
65. Senger DR, Brown LF, Claffey KP, Dvorak HF. Vascular permeability factor, tumour angiogenesis and stroma generation. Invasion Metastasis 1994-5;14:385-94.
66. Charnock-Jones DS, Sharkey AM, Boocock CA, et al. Vascular endothelial growth factor receptor localisation and activation in human trophoblast and choriocarcinoma cells. Biol Reprod. 51:1994;524-530.
67. Liu B, Earl HM, Baban D, et al. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem Biophys Res Commun. 217:1995;721-727.
68. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases balanced proliferation and apoptosis in the presence of angiogenesis suppression . Nat Med. 1:1995;149-153.
69. Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene KDR, in hematopoietic cells and inhibitor effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 55:1995;5687-5692.
70. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
71. Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor. Cancer Res. 55:1995;5296-5301.
72. Cheng S-Y, Huang H-JS, Nagane M, et al. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA. 93:1996;8502-8507.
73. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 56:1996;393-401.
74. Millauer B, Longhi MP, Plate KH, et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. 56:1996;1615-1620.
75. Strawn LM, McMahon G, App H, et al. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3545.
76. Rastinejad F, Polverini PJ, Bouck NP. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell. 56:1989;345-355.
77. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 54:1994;6504-6511.
78. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
79. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med. 1:1995;120-122.